Superbug News

The Superbug Stock Review. Deadly Antibiotic-Resistant Bacteria like ‘Candida Auris’ and Deadly and Virulent Viruses Like ‘CoronaVirus’ or ‘HIV’ which killed 32 million. If Wall Street’s Funded Biotechs Are Trying to Kill What Wants to Kill Us, We’ll Follow It.

Video: How Superbugs Get Started.

A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening...
coronavirus, biotech stock review

VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop...

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...

CoronaVirus Stocks in the News (Bloomberg, Benzinga).

INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40   Alpha Pro Tech, Ltd. (NYSE: APT)...
Citius Pharmaceutical, CTXR, Biotech Stock Review

Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below. Auris all over the room, even on the ceiling?.
AR THreats Report, Biotech Stock Reciew

AR Threats Report (CDC)

This report is dedicated to the 48,700 familieswho lose a loved one each year to antibiotic resistanceor Clostridioides difficile, and the...
Dyadic, Biotech Stock Review

Dyadic (DYAI) Highlights.

"In just over a year and a half we have entered into over 15 proof of concept collaborations for both human and...

Adding Citius (CTXR) $0.55 to Watch List.

Best Presentation at Dawson James Conference. We attended the Dawson James Conference on October 29th, which had over 20...
Dyadic, Biotech Stock Review

Dyadic (DYAI) $7.00 Called a ‘Gamechanger’ – Gets $14 Price Target.

Highly Respected Wall Street Analyst Jason Kolbert Issues $14.00 Price Target On Dyadic.

Latest article

Clorox and P&G Struggle to Meet COVID-19-Related Spike in Demand (MarketWatch).

Clorox shares have soared more than 54% for the year to date, an increase of $11.5 billion to $29.5 billion.

Video: 2020 Year of Crisis: Markets Melt Up (Bloomberg). Ask Yourself a Question, Do I Feel...
Biotech Stock Review, Aphex BioCLeanse

Adding Aphex BioCleanse Systems (SNST) to CoronaVirus Watch List.

Former Eastman Kodak Scientist Engineers Develop Liquid Germ Killer Hy-IQ™ Water to Revolutionize how Deadly Bacteria and Virus are Eradicated